{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T17:56:08Z","timestamp":1767981368637,"version":"3.49.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Serum Institute of India Pvt. Ltd."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.urolonc.2020.01.002","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T05:14:21Z","timestamp":1581052461000},"page":"433-439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["A prospective comparative study to assess the efficacy and tolerability of 2 different doses of intravesical bacillus Calmette-Guerin (BCG) in patients with non\u2013muscle-invasive bladder cancer"],"prefix":"10.1016","volume":"38","author":[{"given":"Rajeev","family":"Sood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitt","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhuvaneshwari","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pramod","family":"Pujari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Shewale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2020.01.002_bib0001","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.eursup.2009.06.009","article-title":"Intravesical instillation treatment of non\u2010muscle\u2010invasive bladder cancer","volume":"8","author":"Braasch","year":"2009","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.urolonc.2020.01.002_bib0002","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/j.1464-410X.2008.07968.x","article-title":"Risk-adapted use of intravesical immunotherapy","volume":"102","author":"Braasch","year":"2008","journal-title":"BJU Int"},{"issue":"Suppl. 3","key":"10.1016\/j.urolonc.2020.01.002_bib0003","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1086\/314064","article-title":"Efficacy and safety of bacille Calmette-Gu\u00e9rin immunotherapy in superficial bladder cancer","volume":"31","author":"Lamm","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.urolonc.2020.01.002_bib0004","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/iju.13410","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin instillation in non-muscle-invasive bladder cancer: a review","volume":"25","author":"Saluja","year":"2018","journal-title":"Int J Urol"},{"issue":"49","key":"10.1016\/j.urolonc.2020.01.002_bib0005","doi-asserted-by":"crossref","first-page":"e2176","DOI":"10.1097\/MD.0000000000002176","article-title":"Low-dose versus standard dose of bacillus Calmette-Guerin in the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis","volume":"94","author":"Zeng","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.urolonc.2020.01.002_bib0006","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.01.002_bib0007","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0022-5347(17)40002-4","article-title":"A randomized prospective study in 202 patients with superficial bladder cancer","volume":"143","author":"Martinez-Pineiro","year":"1990","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2020.01.002_bib0008","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0022-5347(17)55282-9","article-title":"Bacille Calmette-Guerin immunotherapy of superficial bladder cancer","volume":"124","author":"Lamm","year":"1980","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2020.01.002_bib0009","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"issue":"17","key":"10.1016\/j.urolonc.2020.01.002_bib0010","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","article-title":"A randomised trial of intravesical doxorubicin and immunotherapy with bacille Calmette Guerin for transitional cell carcinoma of bladder","volume":"325","author":"Lamm","year":"1991","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.urolonc.2020.01.002_bib0011","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"B\u00f6hle","year":"2003","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.01.002_bib0012","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0094-0143(21)00424-9","article-title":"Long-term results of intravesical therapy for superficial bladder cancer","volume":"19","author":"Lamm","year":"1992","journal-title":"Urol Clin North Am"},{"issue":"4","key":"10.1016\/j.urolonc.2020.01.002_bib0013","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.01.002_bib0014","series-title":"Guidelines on Ta, T1 (non-muscle invasive) bladder cancer. European Association of Urology Guidelines","first-page":"1","author":"Oosterlinck","year":"2006"},{"issue":"1","key":"10.1016\/j.urolonc.2020.01.002_bib0015","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/iju.12609","article-title":"Efficacy and tolerance of one-third full dose bacillus Calmette-Gu\u00e9rin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study","volume":"22","author":"Pfister","year":"2015","journal-title":"Int J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2020.01.002_bib0016","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0022-5347(17)37707-8","article-title":"A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective?","volume":"146","author":"Pagano","year":"1991","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2020.01.002_bib0017","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.urology.2007.07.017","article-title":"The safety and efficacy of different doses of bacillus Calmette Gu\u00e9rin in superficial bladder transitional cell carcinoma","volume":"70","author":"Agrawal","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2020.01.002_bib0018","first-page":"317","article-title":"A randomized trial comparing low dose (40 or 80 mg) with standard dose (120 mg) of bacillus Calmatte-Guerin for superficial bladder cancer","volume":"22","author":"Vijjan","year":"2007","journal-title":"Indian J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2020.01.002_bib0019","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.aju.2015.07.002","article-title":"A comparative study between full-dose and half-dose intravesical immune bacille Calmette-Gu\u00e9rin injection in the management of superficial bladder cancer","volume":"13","author":"Kandeel","year":"2015","journal-title":"Arab J Urol"},{"key":"10.1016\/j.urolonc.2020.01.002_bib0020","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.urols.2014.07.002","article-title":"Maintenance bacillus Calmette-Guerin therapy prolongs recurrence-free survival in non-muscle-invasive bladder cancer: a real-world experience","volume":"26","author":"Liu","year":"2015","journal-title":"Urol Sci"},{"issue":"3","key":"10.1016\/j.urolonc.2020.01.002_bib0021","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU Cancers Group Randomized Study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"issue":"22","key":"10.1016\/j.urolonc.2020.01.002_bib0022","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.3760\/cma.j.issn.0366-6999.20141045","article-title":"Reduced dose of bacillus Calmette-Gu\u00e9rin versus full dose of bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer after transurethral resection bladder tumor: a meta-analysis of randomized controlled trials","volume":"127","author":"Qin","year":"2014","journal-title":"Chin Med J"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392030003X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392030003X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:18:29Z","timestamp":1761041909000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814392030003X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S107814392030003X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.01.002","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A prospective comparative study to assess the efficacy and tolerability of 2 different doses of intravesical bacillus Calmette-Guerin (BCG) in patients with non\u2013muscle-invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}